H.C. Wainwright raised the firm's price target on Revolution Medicines to $195 from $169 and keeps a Buy rating on the shares after the company presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO. Daraxonrasib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and overall survival, the two co-primary endpoints, notes the analyst, who sees these "practice-changing results" derisking the ongoing Phase 3 RASolve 301 and RASolute 303, 304, and 309 trials.
